4//SEC Filing
Smith Brendan 4
Accession 0001209191-23-011790
CIK 0001674416other
Filed
Feb 21, 7:00 PM ET
Accepted
Feb 22, 5:41 PM ET
Size
9.2 KB
Accession
0001209191-23-011790
Insider Transaction Report
Form 4
Smith Brendan
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Shares
2023-02-18+3,825→ 6,464 total - Tax Payment
Common Shares
2023-02-21$48.26/sh−1,392$67,178→ 5,072 total - Exercise/Conversion
Restricted Stock Units
2023-02-18−3,825→ 11,475 total→ Common Shares (3,825 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
- [F2]Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
- [F3]This restricted stock unit award was granted on February 18, 2022 with respect to 15,300 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.
Documents
Issuer
CRISPR Therapeutics AG
CIK 0001674416
Entity typeother
Related Parties
1- filerCIK 0001857492
Filing Metadata
- Form type
- 4
- Filed
- Feb 21, 7:00 PM ET
- Accepted
- Feb 22, 5:41 PM ET
- Size
- 9.2 KB